Rubius Therapeutics to Participate in the Morgan Stanley 16th Annual Global Healthcare Conference
A live audio webcast will be available within the Investors & Media section of Rubius’ website. An archived replay will be accessible for 90 days following the event.
About Rubius Therapeutics
Rubius Therapeutics is a biopharmaceutical company pioneering the development of a new class of medicines called Red Cell Therapeutics™. The Company’s proprietary RED PLATFORM™ was designed to genetically engineer and culture Red Cell Therapeutics™ that are selective, potent and ready-to-use cellular therapies for the potential treatment of several diseases across multiple therapeutic areas. Rubius’ initial focus is to advance RCT™ product candidates for the treatment of rare diseases, cancer and autoimmune diseases by leveraging three distinct therapeutic modalities — cellular shielding, potent cell-cell interaction and tolerance induction. For more information, visit www.rubiustx.com or follow us on Twitter.
+1 (973) 271-6085
Vice President, Corporate Communications and Investor Relations
+1 (617) 949-5296
Source: Rubius Therapeutics